NEJM· Luke J. LaffinCleveland Clinic Coordinating Center for Clinical Research, ClevelandStephen J. NichollsVictorian Heart Institute, Melbourne, VIC, AustraliaRussell S. ScottNew Zealand Clinical Research, Christchurch, New ZealandPeter M. CliftonRoyal Adelaide Hospital, Adelaide, SA, AustraliaRenate KoopsAotearoa Clinical Trials, Auckland, New ZealandAshish SarrajuCleveland Clinic Coordinating Center for Clinical Research, ClevelandShweta SinghCRISPR Therapeutics, BostonQiuqing WangKathy WolskiCleveland Clinic Coordinating Center for Clinical Research, ClevelandHuansheng XuJen NielsenNaimish PatelJason M. DuranCRISPR Therapeutics, BostonSteven E. NissenCleveland Clinic Coordinating Center for Clinical Research, Cleveland·· 2026-08-28精选AI 评分60
靶向 ANGPTL3 的 CRISPR-Cas9 基因编辑疗法 CTX310 持久性研究
Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310
AI 导读
NEJM 提前在线发表研究，评估靶向 ANGPTL3 的 CRISPR-Cas9 基因编辑疗法 CTX310 的持久性。作者来自 Cleveland Clinic、Victorian Heart Institute、CRISPR Therapeutics 等机构，目前仅见摘要，具体数据尚未披露。
来源：NEJM · nejm.org